Girolama Alessandra Marfia
Biographic Data
| ID | 7852806 |
|---|---|
| NAME | Girolama Alessandra Marfia |
| GIVEN NAMES | Girolama Alessandra |
| FAMILY NAME | Marfia |
| SIGNATURE | MARFIA G A |
| AFFILIATIONS | University of Rome Tor Vergata |
| ORCID | 0000-0001-5863-7758 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Investigating depression in multiple sclerosis
This Delphi study highlights the need for tailored diagnostic tools and integrated treatment approaches for managing depression in MS. Further studies are required to refine guidelines for the use of antidepressants and explore the role of disease-modifying therapies (DMTs) in treating depression in this population
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
A considerable proportion of MS patients did not achieve a complete CD19 cell depletion and these patients had a higher baseline CD19 cell count. These findings, together with the higher MRI activity found in FR patients, suggest that the Ocrelizumab dosage could be tailored depending on CD19 cell counts at baseline in order to achieve complete disease control in all patients
No prominent works on this page.
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
A considerable proportion of MS patients did not achieve a complete CD19 cell depletion and these patients had a higher baseline CD19 cell count. These findings, together with the higher MRI activity found in FR patients, suggest that the Ocrelizumab dosage could be tailored depending on CD19 cell counts at baseline in order to achieve complete disease control in all patients
Investigating depression in multiple sclerosis
This Delphi study highlights the need for tailored diagnostic tools and integrated treatment approaches for managing depression in MS. Further studies are required to refine guidelines for the use of antidepressants and explore the role of disease-modifying therapies (DMTs) in treating depression in this population
Medicine (2 works) · Multiple Sclerosis Research Studies (2 works) · Antibody (1 work) · Biology (1 work) · Cancer Research (1 work) · CD19 (1 work) · Cell (1 work) · Clinical Psychology (1 work) · Clinical Psychology (1 work) · Delphi method (1 work)